This weekend ACSH trustee Dr. Henry Miller had a letter to the editor appear in the New York Times. Dr. Miller's letter called for more FDA reforms, he wrote that the agency's most significant problems are "mismanagement and a culture that is excessively risk-averse." Dr. Miller calls for "competent management, discipline in the ranks, more effective risk-benefit balancing, a commitment to permitting patients to assume more responsibility for the risk of medicines and the banishment of politics from regulatory decisions and policy." Dr.
This weekend ACSH trustee Dr. Henry Miller had a letter to the editor appear in the New York Times. Dr. Miller's letter called for more FDA reforms, he wrote that the agency's most significant problems are "mismanagement and a culture that is excessively risk-averse." Dr. Miller calls for "competent management, discipline in the ranks, more effective risk-benefit balancing, a commitment to permitting patients to assume more responsibility for the risk of medicines and the banishment of politics from regulatory decisions and policy." Dr. Miller's letter is not a surprise to ACSH staffers -- at a time when most scientists and doctors are afraid to speak up Dr. Miller is a welcome anomaly, always writing op-eds and letters to the editor.
